12 Questions to Ask Before Choosing a Pharma Serialization Vendor (And How to Evaluate the Answers)

Selecting a pharmaceutical serialization vendor is not a commodity purchase.

A poorly chosen system means months of failed validation, FDA non-compliance, production downtime, and a painful, expensive vendor switch.

The wrong choice in 2024 is still causing problems for US manufacturers in 2026.

This guide gives you the exact questions you should ask every vendor before signing a contract and tells you what a satisfactory answer looks like.

Use it as a scorecard in your evaluation process.

The 12 Questions:

Q1: Do you have a physical presence in the United States?

Why it matters: Remote-only vendors mean US-time-zone delays, expensive international travel for on-site issues, and no local accountability.

For a pharma line running 24/7, a vendor who cannot dispatch an engineer within hours is a liability.

What good looks like: A US office with local service engineers.

Q2: Is your system validated to 21 CFR Part 11 and GAMP 5?

Why it matters: FDA requires electronic records and signatures on pharmaceutical systems to comply with 21 CFR Part 11.

GAMP 5 provides the validation framework.

If a vendor cannot produce validation documentation, your system is not FDA-ready.

What good looks like: Pre-written IQ/OQ/PQ protocols, a complete validation package, and experience guiding pharmaceutical QA teams through FDA audits.

Q3: How long does implementation take, and what does that include?

Why it matters: Vendors who quote ‘3 months’ and deliver in 9 are common in this industry.

Understand exactly what is included: hardware delivery, software configuration, line integration, validation, and operator training.

What good looks like: A fixed-scope implementation plan with defined milestones, not a time-and-materials estimate.

Q4: What happens when the system goes down?

Why it matters: Your production line cannot stop because a serialization system failed.

You need to understand exactly what your SLA guarantees: response time, resolution time, escalation path, and whether your system can operate in bypass mode while being repaired.

What good looks like: A documented SLA with guaranteed response times in US business hours, 24/7 remote monitoring, and a local engineer who can arrive on-site within hours.

Q5: Does your software charge per serial number?

Why it matters: Some vendors charge per serial number generated.

At scale, millions of units per year, this adds up dramatically and makes your compliance cost unpredictable.

What good looks like: A flat-fee pricing model with no per-serial charges.

Q6: Can your system integrate with our ERP (SAP / Oracle / other)?

Why it matters: Manual data entry between your serialization system and ERP means errors, delays, and audit failures.

The system must integrate automatically.

What good looks like: Pre-built integration modules for major ERP systems, with documented API specifications.

Q7: Is your software developed in-house or licensed from a third party?

Why it matters: If the vendor licenses their software from another company, you have two vendors responsible for your system, neither fully accountable.

In-house development means faster bug fixes, direct access to developers, and a roadmap the vendor controls.

What good looks like: Proprietary software developed, maintained, and updated by the vendor’s own engineering team.

Q8: Can you handle both serialization AND aggregation on the same system?

Why it matters: Many vendors offer serialization but treat aggregation as an optional add-on or a separate product.

A fragmented system means integration issues and data gaps in your DSCSA compliance chain.

What good looks like: An integrated hardware-software solution covering L1 through L5 with serialization and aggregation managed by one system.

Q9: How do you handle regulatory updates as FDA requirements change?

Why it matters: DSCSA requirements have already evolved, and they will continue to do so.

A system that cannot update to new requirements without a full reinstallation is a long-term compliance risk.

What good looks like: Software updates included in the SLA, with a clear process for implementing regulatory changes without production disruption.

Q10: Can you retrofit our existing packaging line without shutdown?

Why it matters: Full line replacements are expensive and require regulatory revalidation.

A vendor who can modularly upgrade your existing line saves significant cost and downtime.

What good looks like: A proven retrofit methodology and modular hardware that integrates with your existing line equipment.

Q11: What references can you provide from US pharma manufacturers?

Why it matters: Global case studies from India or Europe are not the same as US deployments.

US FDA requirements, line speeds, and packaging formats are specific.

What good looks like: At least three US-based pharma manufacturer references willing to speak with you.

Q12: What is your roadmap for AI and machine learning in inspection?

Why it matters: AI-driven vision inspection is rapidly becoming the standard for defect detection.

A vendor without an AI roadmap is falling behind the market.

What good looks like: Deployed AI/ML capabilities in their current vision inspection systems, not a promise for ‘future releases’.

HOW JEKSON VISION ANSWERS THESE 12 QUESTIONS: US office in West Berlin, NJ | 21 CFR Part 11 + GAMP 5 validated | Flat-fee SLA (ReeServ) | In-house software (REETRAK, ReeView, REESOURCE) | Integrated serialization + aggregation L1-L5 | Retrofittable modular systems | AI-powered vision inspection (ReeView).

Ask us any of these questions directly — we will give you a straight answer. marketing@jeksonvision.com